Skip to main content
FDA grants orphan status to Rafael's AML drug

The FDA granted orphan drug status to Rafael Pharmaceuticals' CPI-613, or devimistat, which is being developed as a treatment for patients ages 60 and older with relapsed/refractory acute myeloid leukemia. The company's ongoing late-stage study of the candidate in combination with chemotherapy is expected to be finished in October 2022.

Full Story: